Oxford Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Oxford Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-54,801	Closed	-$134K	–	684
2025 Q2	$134K	Buy	54,801 +42,492	+345%	+$215K	0.04%	461
2025 Q1	$82.1K	Buy	+12,309	New	+$122K	0.04%	432
2018 Q3	–	Sell	-17,303	Closed	-$334K	–	1887
2018 Q2	$334K	Sell	17,303 -29,078	-63%	-$550K	0.01%	1467
2018 Q1	$870K	Buy	+46,381	New	+$756K	0.02%	999
2017 Q1	–	Sell	-25,298	Closed	-$617K	–	1463
2016 Q4	$617K	Buy	+25,298	New	+$722K	0.02%	557
2016 Q3	–	Sell	-3,975	Closed	-$118K	–	840
2016 Q2	$118K	Buy	+3,975	New	+$140K	﹤0.01%	727
2016 Q1	–	Sell	-2,519	Closed	-$115K	–	880
2015 Q4	$115K	Buy	+2,519	New	+$110K	﹤0.01%	830

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Oxford Asset Management's RCKT Position: Q3 2025 in Review

Oxford Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 54,801 shares — an estimated $134K sold.

Oxford Asset Management first reported a position in RCKT in Q4 2015 and held it in 7 quarters. The position peaked at $870K in Q1 2018. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

Oxford Asset Management reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Oxford Asset Management sold 54,801 Rocket Pharmaceuticals shares in Q3 2025, an estimated $134K.
Oxford Asset Management first reported a position in Rocket Pharmaceuticals in Q4 2015 and held it in 7 quarters.
Oxford Asset Management's Rocket Pharmaceuticals position peaked at $870K in Q1 2018.
173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Oxford Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.